

## Vector pCAGGS Containing the Marburg Marburgvirus, Musoke VP35 Gene with N-Terminal HA Tag

Catalog No. NR-49213

For research use only. Not for human use.

### Contributor and Manufacturer:

Christopher F. Basler, Ph.D., Department of Microbiology, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, New York, USA

### Product Description:

The VP35 polymerase complex protein gene from Marburg marburgvirus (MARV), Musoke (GenBank: DQ217792) was directionally subcloned into a modified pCAGGS mammalian expression vector.<sup>1</sup> The resulting plasmid encodes a recombinant MARV VP35 containing an HA-tag (YPYDVPDYA) and three additional alanine residues at the amino terminus. The plasmid was produced in *Escherichia coli* and extracted.

VP35 is a component of the marburgvirus nucleocapsid<sup>2</sup> and an essential cofactor in the filoviral RNA-dependent RNA polymerase complex.<sup>3</sup> It also binds dsRNA and antagonizes host cell interferon induction at multiple levels.<sup>4</sup>

NR-49213 has been qualified for use in bacterial transformations.

### Material Provided:

Each vial contains approximately 50 µL of plasmid DNA. The DNA concentration and content are shown on the Certificate of Analysis. The vial should be centrifuged prior to opening.

### Packaging/Storage:

NR-49213 was packaged aseptically in screw-capped plastic cryovials. The product is provided frozen on dry ice and should be stored at -20°C or colder immediately upon arrival. Freeze-thaw cycles should be minimized.

### Citation:

Acknowledgment for publications should read "The following reagent was obtained through BEI Resources, NIAID, NIH: Vector pCAGGS Containing the Marburg Marburgvirus, Musoke VP35 Gene with N-Terminal HA Tag, NR-49213."

### Biosafety Level: 1

Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. Biosafety in Microbiological and Biomedical Laboratories. 5th ed. Washington, DC: U.S. Government Printing Office, 2009; see

[www.cdc.gov/biosafety/publications/bmbL5/index.htm](http://www.cdc.gov/biosafety/publications/bmbL5/index.htm).

### Disclaimers:

You are authorized to use this product for research use only. It is not intended for human use.

Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at [www.beiresources.org](http://www.beiresources.org).

While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government makes any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate.

This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products.

### Use Restrictions:

**This material is distributed for internal research, non-commercial purposes only.** This material, its product or its derivatives may not be distributed to third parties. Except as performed under a U.S. Government contract, individuals contemplating commercial use of the material, its products or its derivatives must contact the contributor to determine if a license is required. U.S. Government contractors may need a license before first commercial sale.

### References:

1. Basler, C. F., Personal Communication.
2. Elliott, L. H., M. P. Kiley, and J. B. McCormick. "Descriptive Analysis of Ebola Virus Proteins." *Virology* 147 (1985): 169-176. PubMed: 4060597.
3. Mühlberger, E., et al. "Three of the Four Nucleocapsid Proteins of Marburg Virus, NP, VP35, and L, are Sufficient to Mediate Replication and Transcription of Marburg Virus-Specific Monocistronic Minigenomes." *J Virol* 72 (1998): 8756-8764. PubMed: 9765419.
4. Ramanan, P., et al. "Structural Basis for Marburg Virus VP35-Mediated Immune Evasion Mechanisms." *Proc. Natl. Acad. Sci. U.S.A.* 109 (2012): 20661-20666. PubMed: 23185024.

ATCC® is a trademark of the American Type Culture Collection.

